Talk:Minimal residual disease

Medicine: Hematology-oncology Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Hematology-oncology task force.

Clean-up

I will help clean-up this page. I am going to start with style and grammar edits. I am also going to modify MRD detection of the BCR-ABL t(9;22) translocation in CML is standard of care in most developed countries and is not limited to clinical trials. It extremely important for the monitoring of imatinib mesilate (Gleevec/Glivec)treatment and is in widespread use. I look forward to working with everyone to make this page an excellent wikipedia entry. BTW, I have been developing and performing molecular diagnostic tests for leukemia and lymphoma MRD for over 10 years. Rcubbon (talk) 18:42, 19 February 2008 (UTC)[reply]

I don't really like the second section. I feel that the leukemia background is covered well in the leukemia wikipedia page. I would like to remove it entirely and go with a briefer description of the theory behind MRD (i.e. resistant clones, leukemia stem cells )and combine it with the Significance of MRD section. 63.202.236.181 (talk) 23:56, 26 February 2008 (UTC)[reply]

The article is too focussed on leukaemia

MRD is a general concept in cancer biology and therefore the article should not have such a strong focus on leukaemia 81.98.98.171 (talk) 08:06, 5 June 2022 (UTC)[reply]